Form 8-K - Current report:
SEC Accession No. 0001193125-24-283673
Filing Date
2024-12-23
Accepted
2024-12-23 07:27:01
Documents
16
Period of Report
2024-12-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d920508d8k.htm   iXBRL 8-K 35843
2 EX-10.1 d920508dex101.htm EX-10.1 294747
3 EX-99.1 d920508dex991.htm EX-99.1 13856
7 GRAPHIC g920508g1223055456847.jpg GRAPHIC 3575
  Complete submission text file 0001193125-24-283673.txt   561586

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA tcrx-20241220.xsd EX-101.SCH 2857
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE tcrx-20241220_lab.xml EX-101.LAB 17979
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tcrx-20241220_pre.xml EX-101.PRE 11263
18 EXTRACTED XBRL INSTANCE DOCUMENT d920508d8k_htm.xml XML 3630
Mailing Address 880 WINTER STREET WALTHAM MA 02451
Business Address 880 WINTER STREET WALTHAM MA 02451 857-399-9500
TScan Therapeutics, Inc. (Filer) CIK: 0001783328 (see all company filings)

EIN.: 825282075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40603 | Film No.: 241569873
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)